{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125"}]}],"title":"Patients with any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66"}]}],"title":"Patients with any TEAE related to IP"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Patients with any SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"Patients with TEAE leading to discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Patients discontinued due to IP related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Patients with any adverse event leading to death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"}],"units":"Participants"}],"description":"* Incidence of adverse events throughout the study\n* Incidence and severity of injection site reactions throughout the study","groups":[{"description":"Testosterone enanthate administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.\n\nTestosterone enanthate auto-injector Dose Adjustment 50 mg / 75 mg / 100 mg","id":"OG000","title":"Testosterone Enanthate Auto-injector"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"TEAE (Treatment-emergent adverse event)s were defined as any event that started on or after the first dosing of IP (Investigational Product), or existed prior to the first dose and worsened in severity or relatedness to IP after dosing. The Population consisted of all patients who received at least 1 dose of the investigational product.","reportingStatus":"POSTED","timeFrame":"52 weeks","title":"Safety and Tolerability","type":"SECONDARY","unitOfMeasure":"Participants"}